Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis
- 1 December 1989
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Neurologie
- Vol. 236 (8) , 445-447
- https://doi.org/10.1007/bf00328503
Abstract
Thirty-two patients affected by amyotrophic lateral sclerosis (ALS) were included in a controlled, open therapeutic trial with branched chain amino acids (BCAA). Patients with bulbar muscle involvement were evaluated separately. No statistically significant differences were found in the clinical outcome between the patients treated and the control groups. Blood l-glutamate levels measured in eight patients were normal. The failure of BCAA in the treatment of the patients could be due to different disorders with unpredictable outcome included under the diagnosis of ALS.Keywords
This publication has 17 references indexed in Scilit:
- Free amino acid concentrations in spinal tissue from patients dying of motor neuron diseaseActa Neurologica Scandinavica, 2009
- The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosisAnnals of Neurology, 1988
- PILOT TRIAL OF BRANCHED-CHAIN AMINOACIDS IN AMYOTROPHIC LATERAL SCLEROSISThe Lancet, 1988
- Free amino acid pattern of cerebrospinal fluid in amyotrophic lateral sclerosisActa Neurologica Scandinavica, 1988
- Brain glutamate deficiency in amyotrophic lateral sclerosisNeurology, 1987
- Abnormal glutamate metabolism in amyotrophic lateral sclerosisAnnals of Neurology, 1987
- Familial adult motor neuron disease: amyotrophic lateralsclerosisNeurology, 1986
- Free amino acid levels in amyotrophic lateral sclerosisAnnals of Neurology, 1978
- The administration of guanidine in amyotrophic lateral sclerosisNeurology, 1974
- l-Glutamate UV-Assay with Gutamate Dehydrogenase and NADPublished by Elsevier ,1974